Cost Effectiveness of Azithromycin Versus Cefuroxime, with/without Erythromycin, in Hospitalized Patients with Community Acquired Pneumonia.
Abstract
The purpose of this report is to assess the cost-effectiveness of azithromycin monotherapy for hospitalized patients with community acquired pneumonia against the current practice of a second generation cephalosporin with/without erythromycin. A pharmacoeconomic analysis from the hospital perspective was performed on 266 evaluable patients from a multicenter clinical trial which was conducted from 1993-1995. No significant differences in clinical success or adverse events rates were detected. Health care resource utilization was extracted from the data base were transformed/converted to national costs. A sensitivity analysis was performed and statistics applied to the cost-effectiveness ratios.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 12, 1999
- Accession Number
- ADA360133
Entities
People
- Larry D. Gudgel
Organizations
- Air Force Institute of Technology